Biologics, Inc. Joins MedImpact Direct Specialty Program’s Specialty Pharmacy Network: Innovative Hub Conducts Prescription-Level Utilization Management
CARY, N.C. (January 17, 2018) —Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, is […]
Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy
[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.29.3″][et_pb_column type=”4_4″ _builder_version=”3.29.3″][et_pb_text _builder_version=”4.4.3″] Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes […]
BAVENCIO® (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.
CARY, N.C. (March 28, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by EMD Serono to be […]
Biologics, Inc. Announces New Oncology Partnership
CARY, NC — February 1, 2016 — Biologics, Inc. has been selected by TESARO, Inc. as the exclusive specialty pharmacy provider […]
PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.
CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology […]
Ibrance® (palbociclib) approved for ER+, HER2- advanced breast cancer, available immediately at Biologics, Inc.
CARY, NC — February 5, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Biologics has been […]
Jakafi® (ruxolitinib) approved for new indication, available at Biologics
CARY, NC — December 12, 2014 — Biologics, a specialty pharmacy provider for Jakafi (ruxolitinib), is pleased to announce the U.S. […]